Want to learn more about the high stakes of oncology trials? Check out our detailed infographic filled with eye-opening statistics, such as:
The consequences of low or slow enrollment are clear—especially within underrepresented groups. Without the required enrollment numbers, trial objectives cannot be met, which could lead to abandonment of a promising compound. Slow enrollment leads to longer study duration, and longer study duration means increased costs and a delay in providing promising treatments to patients.
In phase III oncology studies, the cost per patient averages $75,000, and in early phase trials the cost per patient averages over $120,000. Within certain indications, the treatment landscape can shift quickly, and new therapies introduced during the course of a clinical trial can change the standard of care and may make certain aspects of ongoing trials obsolete or unethical.
Slow enrollment can also lead to waning interest and increased turnover on the part of investigators and their staff. This results in having fewer experienced site personnel who are best able to communicate with patients about opportunities for trial participation.